Emerald Advisers’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.25M Buy
1,356
+335
+33% +$340K 0.04% 137
2025
Q4
$1.1M Sell
1,021
-26
-2% -$24.9K 0.03% 134
2025
Q3
$799K Hold
1,047
0.03% 156
2025
Q2
$816K Sell
1,047
-234
-18% -$182K 0.03% 148
2025
Q1
$1.06M Sell
1,281
-311
-20% -$259K 0.05% 127
2024
Q4
$1.23M Sell
1,592
-281
-15% -$233K 0.05% 131
2024
Q3
$1.66M Buy
1,873
+804
+75% +$723K 0.06% 123
2024
Q2
$968K Buy
1,069
+341
+47% +$273K 0.04% 142
2024
Q1
$566K Sell
728
-69
-9% -$49.1K 0.02% 174
2023
Q4
$465K Buy
+797
New +$465K 0.02% 179
2023
Q1
Sell
-864
Closed -$316K 239
2022
Q4
$316K Sell
864
-21
-2% -$7.45K 0.02% 186
2022
Q3
$286K Sell
885
-64
-7% -$20.3K 0.01% 194
2022
Q2
$308K Buy
+949
New +$285K 0.02% 196
2014
Q3
Sell
-4,248
Closed -$264K 384
2014
Q2
$264K Sell
4,248
-1,481
-26% -$88.4K 0.01% 325
2014
Q1
$337K Sell
5,729
-1,433
-20% -$80K 0.02% 310
2013
Q4
$365K Buy
7,162
+512
+8% +$25.6K 0.02% 299
2013
Q3
$335K Buy
6,650
+414
+7% +$21.7K 0.02% 306
2013
Q2
$306K Buy
+6,236
New +$339K 0.02% 299

Other funds holding LLY

Emerald Advisers's LLY Position: Q1 2026 in Review

Emerald Advisers increased its Eli Lilly (LLY) stake by 33% in Q1 2026, buying an estimated $340K and bringing the position to 1,356 shares worth $1.25M. The position accounts for 0.04% of the portfolio, ranked #137.

Emerald Advisers first reported a position in LLY in Q2 2013 and has held it in 18 quarters since. The position peaked at $1.66M in Q3 2024. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Emerald Advisers held 1,356 shares of Eli Lilly worth $1.25M as of Q1 2026.
  • Emerald Advisers bought 335 Eli Lilly shares in Q1 2026, an estimated $340K.
  • Eli Lilly made up 0.04% of Emerald Advisers's portfolio in Q1 2026, its #137 holding.
  • Emerald Advisers first reported a position in Eli Lilly in Q2 2013 and has held it in 18 quarters since.
  • Emerald Advisers's Eli Lilly position peaked at $1.66M in Q3 2024.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Emerald Advisers's 13F filing for Q1 2026, filed 4 May 2026.